Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.39 |
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | NCF1 | P14598 | 2/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785695 | 0.76 | LMNA (0.35) | — | |
| SCHEMBL6739736 | 0.68 | NOS3 (0.39) | NOS3NOS2NCF1F12PLAU | |
| SCHEMBL761059 | 0.67 | DYRK1A (0.48) | NOS3NOS2NCF1F12PLAU | |
| SCHEMBL27688039 | 0.67 | NOS3 (0.38) | NOS3NOS2NCF1F12PLAU | |
| SCHEMBL627653 | 0.65 | NOS3 (0.41) | NOS3NOS2NCF1F12PLAU | |
| SCHEMBL6163883 | 0.65 | NOS3 (0.41) | NOS3NOS2NCF1F12PLAU | |
| SCHEMBL4317878 | 0.65 | LIMK1 (0.47) | AURKAKDRAURKBROCK1 | |
| SCHEMBL8140505 | 0.63 | NOS2 (0.41) | NOS3NOS2NCF1F12PLAU | |
| SCHEMBL6742742 | 0.63 | NOS3 (0.42) | NOS3NOS2NCF1F12PLAU | |
| SCHEMBL21295608 | 0.61 | KDM4E (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175419-B1 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-28 | — | — | EP | claimed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | claimed |
| EP-1175419-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2000059902-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | claimed |
| US-6689770-B2 | AN INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1175419-B1 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | WEXLER RUTH R (US) | 2003-03-13 | — | — | US | disclosed |
| US-6399644-B1 | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY | 2002-06-04 | — | — | US | disclosed |
| EP-1175419-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000059902-A2 | ARYL SULFONYLS AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050315-A1 | Aryl sulfonyls as factor Xa inhibitors | F12, F11, TFPI | NOS3 4346/4885NOS2 4618/4885NCF1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.